As of Wednesday close, Cardiff Oncology Inc.’s (NASDAQ:CRDF) stock was up $0.09, moving up 6.98 percent to $1.38. The average number of shares traded per day over the past five days has been 278,360 shares. 4 times new highs have been achieved over the past 5 days, with a $0.0800 gain in that time frame. In the last twenty days, the average volume was 270,045, while in the previous 50 days, it was 425,592.
Since last month, CRDF stock retreated -9.21%. Shares of the company fell to $1.2050 on 11/21/22, the lowest level in the past month. A 52-week high of $7.32 was reached on 01/12/22 after having rallying from a 52-week low of $1.13. Since the beginning of this year, CRDF’s stock price has dropped by -77.04% or -$4.6300, and marked a new high 8 times. However, the stock has declined by -81.15% since its 52-week high.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
CRDF stock investors should be aware that Cardiff Oncology Inc. (CRDF) stock had its last reported insider trading activity 66 days ago on Sep 19. White Lale, the Director of the company, purchased of 15,000 shares for $1.64 on Sep 19. It resulted in a $24,525 investment by the insider. Armitage James O added 13,000 shares at an average price of $1.56 on Sep 16. The insider now owns 13,000 shares following the transaction. On Sep 16, Chief Financial Officer Levine James E. bought 30,000 shares at $1.56 apiece. The transaction was valued at $46,710.
The stock’s beta is 1.53. Besides these, the trailing price-to-sales (P/S) ratio of 151.80, the price-to-book (PB) ratio of 0.53.
In the three months ended June 29, Cardiff Oncology Inc.’s quick ratio stood at 14.50, while its current ratio was 14.50, showing that the company is able to pay off its debt. Based on annual data, CRDF earned $0.36 million in gross profit and brought in $0.36 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -20.60%. Return on equity (ROE) for the past 12 months was -31.30%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. CRDF’s revenue rose 87.27% to $0.2 million during the quarter, while net income inched up to $0.55 million. While analysts expected Cardiff Oncology Inc. to report -$0.25 quarterly earnings, the actual figure was -$0.24 per share, beating the consensus estimate by 4.00%. During the quarter, the company generated -$8.8 million in EBITDA. The liabilities of Cardiff Oncology Inc. were 10.42 million at the end of its most recent quarter ended June 29, and its total debt was $2.98 million. The value of shareholders’ equity is $44.68 million.
This quick technical analysis looks at Cardiff Oncology Inc.’s (CRDF) price momentum. With a historical volatility rate of 68.16%, the RSI 9-day stood at 51.36% on 23 November.
With respect to its five-day moving average, the current Cardiff Oncology Inc. price is up by +6.15% percent or $0.0800. At present, CRDF shares trade -10.97% below its 20-day simple moving average and -47.92% percent below its 100-day simple moving average. However, the stock is currently trading approximately -14.81% below its SMA50 and -58.68% below its SMA200.
Stochastic coefficient K was 43.48% and Stochastic coefficient D was 29.27%, while ATR was 0.1065. Given the Stochastic reading of 66.04% for the 14-day period, the RSI (14) reading has been calculated as 46.86%. As of today, the MACD Oscillator reading stands at 0.0144, while the 14-day reading stands at 0.0114.
William Blair launched its rating on Cardiff Oncology Inc. (NASDAQ: CRDF) to an Outperform in a note to investors on January 05, 2022. Cardiff Oncology Inc. (CRDF) has been rated Buy by analysts. According to 0 brokerage firms, CRDF is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Cardiff Oncology Inc. stock as buy, with 4 recommending it as overweight.
With a median target price of $5.00, the current consensus forecast for the stock is $5.00 – $14.00. Based on these forecasts, analysts predict Cardiff Oncology Inc. (CRDF) will achieve an average price target of $8.00.